anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity-related cognitive dysfunction poses a significant threat to public health. The present study demonstrated mitigating effects of intermittent fasting (IF) and its combination with isomalto-oligosaccharides and IF (IF + IMO) on cognitive impairments induced by a high-fat-high-fructose (HFHF) diet in mice, with IF + IMO exhibiting superior effects. Transcriptomic analysis of the hippocampus revealed that the protective effects on cognition might be attributed to the suppression of toll-like receptor 4 (TLR4)/NFκB signaling, oxidative phosphorylation, and neuroinflammation. Moreover, both IF and IF + IMO modulated the gut microbiome and promoted the production of short-chain fatty acids, with IF + IMO displaying more pronounced effects. IF + IMO-modulated gut microbiota, metabolites, and molecular targets associated with cognitive impairments were further corroborated using human data from public databases Gmrepo and gutMgene. Furthermore, the fecal microbiome transplantation confirmed the direct impacts of IF + IMO-derived microbiota on improving cognition functions by suppressing TLR4/NFκB signaling and increasing BDNF levels. Notably, prior exposure to IF + IMO prevented weight-regain-induced cognitive decline, suppressed TLR4/NFκB signaling and inflammatory cytokines in the hippocampus, and mitigated weight regain-caused gut dysbacteriosis without altering body weight. Our study underscores that IMO-augmented alleviating effects of IF on obesity-related cognitive impairment particularly during weight-loss and weight-regain periods, presenting a novel nutritional strategy to tackle obesity-related neurodegenerative disorders.
UNLABELLED: We would like to provide an updated comprehensive perspective and identify the components linked to chronic spontaneous urticaria (CSU) without specific triggers in autoimmune atrophic gastritis (AAG). AAG is an organ-specific autoimmune disease that affects the corpus-fundus gastric mucosa. Although we lack a unified explanation of the underlying pathways, when considering all paediatric patients reported in the literature, alterations result in gastric neuroendocrine enterochromaffin-like (ECL) cell proliferation and paracrine release of histamine. Several mechanisms have been proposed for the pathogenesis of CSU, with much evidence pointing towards AAG and ECL cell responses, which may be implicated as potential factors contributing to CSU. The excessive production/release of histamine into the bloodstream could cause or trigger exacerbations of CSU in AAG, independent of Helicobacter pylori; thus, the release of histamine from ECL cells may be the primary modulator.
CONCLUSION: Considering the understanding of these interactions, recognising the respective roles of AAG in the pathogenesis of CSU may strongly impact the diagnostic workup and management of unexplained/refractory CSU and may inform future research and interventions in the paediatric population.
WHAT IS KNOWN: • Autoimmune atrophic gastritis is a chronic immune-mediated inflammatory disease characterised by the destruction of the oxyntic mucosa in the gastric body and fundus, mucosal atrophy, and metaplastic changes. • Autoimmune atrophic gastritis in paediatric patients is important because of the poor outcome and risk of malignancy and possibly underestimated entities primarily reported in single-case reports.
WHAT IS NEW: • Upper gastrointestinal inflammatory disorders, independent of H. pylori, have been implicated as potential inducing factors in the development of chronic spontaneous urticaria. • If a paediatric patient presents with symptoms such as anaemia, reduced vitamin B12 levels, recurrent urticaria with no other detectable aetiology, positive anti-parietal cell antibodies, and elevated gastrin levels, autoimmune atrophic gastritis should be considered a possible cause of chronic urticaria.
A mammalian muscle construct and a method for producing the construct are provided. The mammalian muscle construct includes a substrate and a plurality of separate anchors secured to the substrate. Myogenic precursor cells are provided on the substrate with at least some of the cells in contact with the anchors. The myogenic precursor cells are cultured in vitro under conditions to allow the cells to become confluent between the anchors. The anchors are receptive to the cells and allow the cells to attach thereto, such that placement of the anchors controls the size and shape of the muscle construct formed. Specifically, the anchors include separate fragments of biocompatible material secured to the substrate, wherein cell adhesion molecules are associated with each fragment to facilitate attachment of the precursor cells to the fragment.
Aspergillosis disease is a growing problem. These diseases are not yet uncommon in chronic obstructive pulmonary disease patients. (COPD).

Aspergillosis disease are very difficult to be diagnosed or treated. Isolation of aspergillus in sputum of patients is not always responsible of a real disease. Need of treatment is discussed. That is why, we will conduct a prospective cohort study to evaluate aspergillus rate in respiratory samples of COPD patients (GOLD stage III or IV)
CONTEXT: There has been a global increase in the use of electronic cigarettes (EC). However, to our knowledge, no review has summarized or categorized changes in inflammatory biomarkers after EC use in the extant literature.
OBJECTIVE: To evaluate changes in general, cardiopulmonary, and oxidative stress-related inflammatory biomarkers in healthy adults who use ECs.
METHODS: A scoping review was conducted according to the Arksey and O'Malley framework. PubMed and MEDLINE (Ovid) databases were used for our search. After initial pilot searches and discussions, we performed a final search with medical subject headings and plain language terms related to inflammation, biomarkers, ECs, and adult humans. All full-text articles, gray literature, and primary studies dating from the inception of the searched databases to the present were included. Studies of human participants with known confounding medical histories were excluded.
RESULTS: Thirty-seven studies met the inclusion criteria. After short-term (<1 month) use, ECs containing nicotine moderately increased cardiovascular (CV) and oxidative stress markers of inflammation. Of all reported results, 50% of CV biomarkers were increased, and 64% of oxidative stress markers were increased. After long-term (>1 month) use, ECs containing nicotine produced mixed results. Two commonly measured biomarkers in this group, matrix metalloproteinase-9 (MMP-9) and interleukin-6 (IL-6), were elevated in 75% and 60% of measured instances, respectively.
CONCLUSION: The results of studies evaluated in our scoping review suggested that short-term use of nicotine-containing ECs may result in increased CV and oxidative stress inflammation, contributing to potential CV or neurologic disease development. The results of studies evaluated in our scoping review also suggested that long-term use of nicotine-containing ECs resulted in no significant changes in general inflammatory biomarker levels. A rigorous systematic review and meta-analysis is necessary to corroborate our findings and to determine the effect of long-term EC use on MMP-9 and IL-6 levels.
PROBLEM TO BE SOLVED: To obtain a liquid composition, comprising a glucide-based surfactant in a solution of a crystalline compound dissolved therein, excellent in low-temperature stability and hardly causing the deposition of the crystalline compound by preservation at low temperatures. SOLUTION: This liquid composition is obtained by dissolving one or more selected from a fatty acid having an 8-30C alkyl group or its salt (e.g. pentadecanoic acid), an aliphatic alcohol (e.g. decanol) and a salt and a derivative thereof in a solvent such as ethyl alcohol and then including one or more glucide-based surfactants of formulas I, II and III (R1 to R8 are each OH or an 8-22C carboxyl; R9 to R12 are each OH, an 8-12C carboxyl, etc.; R13 is an aglycone residue) therein. Furthermore, 0.1-10wt.% nonionic surfactant having <=10 value of hydrophile-lipophile balance(HLB) (e.g. a sorbitan ester of a fatty acid) is preferably blended therewith. The glucide-based surfactant can suitably be regulated according to the amount, etc., of the blended crystalline compound and 0.001-10wt.% thereof based on the whole liquid composition is blended therein. The composition hardly causes cloudiness of the solution and crystal deposition even when preserved at about 5 deg.C for a long period and can be used as an agent for hair of the head, a cosmetic, a medicine, a manicure, an industrial product, etc.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the novel derivatives of 1,2,3,4- -tetrahydroquinoxalidinedione of the formula (I)   where values A, R, R 1 ,R 2 , X are given in point 1 of the invention claim. Compounds show antagonistic effect with respect to glutamate receptors, high affinity degree to AMPA-receptors that are not NMDA-receptors, strong inhibitory effect directed against neurotoxicity induced by kainic acid, inhibitory effect on audiogenic attack and high degree of solubility. Invention describes also pharmaceutical composition based on compounds of the formula (I). EFFECT: valuable pharmacological properties of compounds. 8 cl, 7 tbl
BACKGROUND AND OBJECTIVES: Craniocervical junction (CCJ) arteriovenous fistulas (AVFs) are rare. Variability in clinical manifestations and treatment strategies for CCJ AVFs stems from differences in their angioarchitecture. Our study aims to categorize CCJ AVFs based on their angioarchitecture and explore the associated clinical features and treatment modalities for distinct CCJ AVF types.
METHODS: The authors conducted a retrospective analysis of patients with CCJ AVFs treated at a single neurosurgical facility over the past decade. These patients were classified based on the angioarchitecture of their CCJ AVFs. The analysis included an evaluation of angioarchitecture, clinical characteristics, treatment strategies, and outcomes.
RESULTS: The study included 155 patients, with a median age of 56 years, collectively manifesting 165 CCJ AVFs. Our classification identified 4 distinct CCJ AVF types: epidural AVFs (19 [11.5%]), dural AVFs (98 [59.4%]), radicular AVFs (33 [20.0%]), and perimedullary AVFs (15 [9.1%]). Further differentiation was applied based on the presence of pial feeders. The predominant fistula location was at cervical-1 (77.0%). Ascending intradural drainage (52.7%) and descending intradural drainage (52.1%) were frequently observed drainage patterns. Patients with dural AVF predominantly presented with venous hypertensive myelopathy, whereas patients with other types of CCJ AVFs showed a higher incidence of subarachnoid hemorrhage (P = .012). Microsurgery was the predominant treatment, applied in the management of 126 (76.4%) AVFs, whereas 8 (4.8%) AVFs exclusively underwent interventional embolization and 25 (15.2%) received a combination of interventional embolization and microsurgical treatment.
CONCLUSION: CCJ AVFs can be distinguished based on the fistula location and the arterial feeders. Currently, microsurgery stands as the preferred treatment strategy for CCJ AVFs, whereas interventional embolization plays a distinctive role in cases with specific angioarchitecture or as a pretreatment measure before microsurgery.
An automated informed consent system uses a computer to inform a patient about a proposed medical procedure and to verify that the patient understands the material presented. The system provides an audiovisual presentation using animation and/or voice-over to aid in the patient's understanding of the procedure and associated risks. The system comprises a patient interface connected to a network wherein the patient interface includes at least one input device for use by the patient to provide input to the interface and a screen for displaying information to the patient. A server connected to the network in operative communication with the patient interface is also included. The server comprises a program stored in memory and accessible by the patient interface. Once a connection between the patient interface and server has been established, the interface is operable under control of the program to present information concerning a medical procedure to the patient via the screen. The patient interface also requests input from the patient via the input device, and determines from the input whether the patient has achieved a predetermined level of understanding of the information presented. The interface is further operable under the control of the program to generate a consent form for the medical procedure for review by a physician and execution by the patient.
Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
PURPOSE:To obtain an auxiliary liquid for drinking medicines, containing an agent for protecting gastric mucous membrane and consisting essentially of water for facilitating internal use of the medicine and to obtain an auxiliary agent for drinking medicine, used by dissolving in water. CONSTITUTION:This auxiliary liquid consisting essentially of water is obtained by adding an agent for protecting gastric mucous membrane (e.g. gastric mucin) to auxiliary liquid so as to facilitate internal use of medicines which are prone to roughen the surface of the stomach. The auxiliary liquid for drinking medicine is sealed in a volume ratio of 50-90% based on total volume into an openable hermetically sealed container to provide a container-housed auxiliary liquid for drinking medicines. A transparent or translucent wide-mouthed bottle made of glass or plastics is preferably used as the hermetically sealed container. This auxiliary agent for drinking medicines is used by dissolving it in water to be drunk when a medicine is internally taken to protect stomach of person having a weak stomach.
The invention relates to a novel hematopathy management system, and aims to provide a comprehensive solution integrating big data analysis and Internet technology for improving treatment and management efficiency of hematopathy patients. The system utilizes advanced sensors and equipment to monitor important physiological parameters of patients in real time and record the use condition of medicines. The acquired data are deeply mined through a big data analysis technology, the system can predict disease risks, discover treatment rules, and formulate a personalized treatment scheme according to the treatment rules. Meanwhile, the system supports remote communication and monitoring between doctors and patients, so that the patients can get timely medical attention even in a home environment. In addition, the system also comprises a health management function, so that the patient is helped to establish a healthy life style, and the life quality is improved. The invention brings more accurate and convenient medical service for the hematopathy patients by an intelligent and personalized management method, and remarkably improves the effectiveness of treatment and the life quality of the patients.
INTRODUCTION: Autoimmune thyroid diseases (AITDs) are prevalent disorders, primarily encompassing Graves' disease (GD) and Hashimoto's thyroiditis (HT). Despite their common occurrence, the etiology of AITDs remains elusive. Th9 cells, a new subset of CD4+T cells with immunomodulatory properties, have been linked to the development of various autoimmune diseases. However, research on the role of Th9 cells in AITDs is limited.
METHODS: We investigated the expression of Th9 cells,their functional cytokine IL-9, and transcription factor IRF4 in peripheral blood mononuclear cells (PBMCs) and plasma of AITD patients and healthy controls. Additionally, we explored the genetic association between four loci polymorphisms (rs31564, rs2069879, rs1859430, and rs2069868) of the IL-9 gene and AITDs.
RESULTS: We reported, for the first time, that refractory GD patients exhibited elevated mRNA levels of IL-9 and IRF4 in PBMCs, increased IL-9 protein levels in plasma, and a higher proportion of Th9 cells in peripheral blood when compared to normal controls. Furthermore, human recombinant IL-9 protein was found to enhance IFN-g secretion in PBMCs from both GD patients and normal controls. At the genetic association level, after adjusting for age and sex, the rs2069879 polymorphism exhibited a significant association with AITDs under an additive model (P<0.001, OR= 0.05, 95% CI=0.03-0.08).
DISCUSSION: Our results reveal that Th9 cells may exert a pivotal role in the pathogenesis and progression of refractory GD and HT, and IL-9 holds promise as a novel therapeutic target for the management of AITDs.
The invention discloses dextral ibuprofen amino acid salt tablets and a preparation method thereof. The tablets are prepared from the following raw materials in part by weight: 1 part of dextral ibuprofen amino acid salt, 0.2 to 20 parts of diluent (or filler), 0.01 to 1 part of adhesive, 0.01 to 1 part of disintegrating agent, 0.01 to 1 part of flavoring agent and 0.001 to 0.1 part of lubricating agent. Wet granulation, dry granulation and tabletting or direct powder tabletting and tablet coating are adopted in the preparation process of the tablets. Based on the dextral ibuprofen, the specification of the tablets can be 30 to 300 milligrams, preferably 37.5 milligrams or integral multiple of 37.5 milligrams. The dextral ibuprofen amino acid salt serving as an effective ingredient of the tablets has the advantages of quick response, accurate dose, low side effect and small individual difference. The tablets can be prepared into common tablets, chewable tablets, effervescent tablets, soluble tablets, oral fast dissolving tablets, sugar coated tablets, film coated tablets and the like.
Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy. The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against .beta.1-adrenergic receptors, ADP-ATP carriers, .alpha. and .beta. myosin heavy chains, and adenine nucleotide translocators. Immunoapheresis treatment using the column results in improvement of hemodynamic parameters such as mean arterial pressure, mean pulmonary pressure, pulmonary capillary wedge pressure, right atrial pressure, cardiac output, cardiac index, stroke volume index, and systemic vascular resistance.
OBJECTIVES: I. Determine the maximum tolerated dose of irinotecan when administered with cisplatin and radiotherapy in patients with locally advanced non-small cell lung carcinoma. II. Determine the toxic effects, especially acute and long-term esophagitis and pneumonitis, of this regimen in these patients. III. Determine the response rate, duration to progression, and sites of relapse in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of irinotecan. Patients receive irinotecan IV over 90 minutes and cisplatin over 1 hour on day 1. Patients also undergo radiotherapy once daily on days 1-5. Treatment repeats every 7 days for 7 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 2 months for 1 year, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 3-27 patients will be accrued for this study within 3 years.
The presence of Factor VIII (FVIII) inhibitor prevents FVIII infusions from working properly and makes treatment of bleeding episodes very difficult. Having an inhibitor is a serious and life-threatening complication in patients with Hemophilia. The usual treatment of patients with FVIII inhibitors involves what is called "immune tolerance induction" (ITI). Immune Tolerance means that the body can accept infused FVIII and that FVIII is again effective in controlling bleeds. ITI involves giving high doses of FVIII regularly until the inhibitor disappears. This treatment is not always effective. The inhibitor persists in about 1 in 5 patients who undergo ITI.

There are 2 types of FVIII concentrates: FVIII concentrates derived from human plasma, which contain VWF, and concentrates of FVIII without VWF. Both types of concentrates are commonly used to induce immune tolerance in patients with Hemophilia A. Retrospective studies on subjects who were treated with VWF containing Factor VIII concentrates after failing ITI with pure factor VIII concentrates, have shown that tolerance can be achieved in a large percentage of patients. This study will access prospectively whether treatment with a FVIII concentrate containing VWF given at a high dose (200 units per kilogram) daily for up to 33 months is able to induce immune tolerance after previous attempts with concentrates containing only FVIII have failed.
Participants who will receive the Cannabidiol Oral Solution (CBD-OS) titrated up to a dose of 12.5 mg/kg administered twice daily for a total dose of up to 25 mg/kg/day for 26 consecutive weeks. Participants will have the option to continue receiving the CBD-OS for an additional 26 weeks, for a total of 52 weeks.
The invention provides a secnidazole vaginal effervescent tablet including secnidazole, a filler, a foaming agent and a foam stabilizer, and the secnidazole accounts for 20-60 wt % in the vaginal effervescent tablet. The foaming agent comprises an acid system comprising acid or acid salt, and an alkali system comprising carbonates. The acid system includes citric acid, tartaric acid, succinic acid, fumaric acid, adipic acid, malic acid, water-soluble amino acid, potassium bitartrate, sodium hydrogen tartrate, sodium bitartrate, potassium dihydrogen citrate, sodium fumarate and boric acid. The alkali system includes sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium bicarbonate and calcium carbonate. The foam stabilizer is a surfactant selected from sodium dodecyl sulfate and Tween 80. The secnidazole vaginal effervescent tablet provided by the invention can be used for preparation of medicaments for treating vaginal infection diseases caused by sensitive anacerobes.